Azacitidine Improves RBC-TI Rates in Patients with Lower-Risk MDS
Original Publication Date
Article Source
External Web Content
CC-486—the oral formulation of azacitidine—significantly improved RBC transfusion independence (RBC-TI) rates and induced durable bilineage improvements in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high-risk disease features, according to a phase 3 clinical…